Shuhua Tan

List of Publications by Year
in descending order

9 papers	114 citations	1478505 6 h-index	1474206 9 g-index
10 all docs	10 docs citations	10 times ranked	167 citing authors

#	Article	IF	Citations
1	Lunasin attenuates oxidant‐induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE$^{-/-}$ mice by up‐regulating heme oxygenase‐1 *via* PI3K/Akt/Nrf2/ARE pathway. FASEB Journal, 2019, 33, 4836-4850.	0.5	34
2	Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression *in vitro* and *in vivo*. Oncotarget, 2017, 8, 80826-80840.	1.8	22
3	Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. Atherosclerosis, 2020, 297, 111-119.	0.8	20
4	Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine, 2021, 65, 103250.	6.1	11
5	A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo. International Journal of Molecular Sciences, 2017, 18, 2064.	4.1	9
6	Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE$^{-/-}$ Mice. Molecules, 2019, 24, 4140.	3.8	7
7	Hirudin as a novel fusion tag for efficient production of lunasin in Escherichia coli. Preparative Biochemistry and Biotechnology, 2017, 47, 619-626.	1.9	6
8	Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo. Biomedicine and Pharmacotherapy, 2018, 98, 271-279.	5.6	4
9	Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines, 2021, 9, 1783.	3.2	1